Replimune Group Inc

Company Profile

Replimune Group Inc had its IPO on 2018-07-20 under the ticker symbol REPL.

The company operates in the Healthcare sector and Biotechnology industry. Replimune Group Inc has a staff strength of 284 employees.

Stock update

Shares of Replimune Group Inc opened at $203 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of $187.05 - $207.9, and closed at $188.95.

This is a -7.17% slip from the previous day's closing price.

A total volume of 39,829 shares were traded at the close of the day’s session.

In the last one week, shares of Replimune Group Inc have increased by +2.16%.

Replimune Group Inc's Key Ratios

Replimune Group Inc has a market cap of $1.16 billion, indicating a price to book ratio of 3.6145 and a price to sales ratio of 0.

In the last 12-months Replimune Group Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-186948000. The EBITDA ratio measures Replimune Group Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Replimune Group Inc’s operating margin was 0% while its return on assets stood at -22.26% with a return of equity of -39.29%.

In Q2, Replimune Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Replimune Group Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Replimune Group Inc’s profitability.

Replimune Group Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.3744. Its price to sales ratio in the trailing 12-months stood at 0.

Replimune Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$603.89 million

Total Liabilities

$32.24 million

Operating Cash Flow

$7.36 million

Capital Expenditure

$449000

Dividend Payout Ratio

0%

Replimune Group Inc ended 2024 with $603.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $603.89 million while shareholder equity stood at $514.03 million.

Replimune Group Inc ended 2024 with $0 in deferred long-term liabilities, $32.24 million in other current liabilities, 57000.00 in common stock, $-535043000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $106.48 million and cash and short-term investments were $539.10 million. The company’s total short-term debt was $3,797,000 while long-term debt stood at $28.91 million.

Replimune Group Inc’s total current assets stands at $550.04 million while long-term investments were $0 and short-term investments were $432.62 million. Its net receivables were $3.05 million compared to accounts payable of $4.88 million and inventory worth $0.

In 2024, Replimune Group Inc's operating cash flow was $7.36 million while its capital expenditure stood at $449000.

Comparatively, Replimune Group Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$188.95

52-Week High

$29.523

52-Week Low

$15.068

Analyst Target Price

$52.11

Replimune Group Inc stock is currently trading at $188.95 per share. It touched a 52-week high of $29.523 and a 52-week low of $29.523. Analysts tracking the stock have a 12-month average target price of $52.11.

Its 50-day moving average was $186.64 and 200-day moving average was $165.19 The short ratio stood at 14.69 indicating a short percent outstanding of 0%.

Around 831.5% of the company’s stock are held by insiders while 9499.4% are held by institutions.